Menu
×
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Today's Hours
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
- Author(s): Takashima H;Takashima H; Yoshida Y; Yoshida Y; Nagura C; Nagura C; Furukawa T; Furukawa T; Tei R; Tei R; Maruyama T; Maruyama T; Maruyama N; Maruyama N; Abe M; Abe M
- Source:
Diabetes & vascular disease research [Diab Vasc Dis Res] 2018 Sep; Vol. 15 (5), pp. 469-472. Date of Electronic Publication: 2018 Jun 20.- Publication Type:
Journal Article; Randomized Controlled Trial- Language:
English - Source:
- Additional Information
- Source: Publisher: Sage Publications Country of Publication: England NLM ID: 101234011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8984 (Electronic) Linking ISSN: 14791641 NLM ISO Abbreviation: Diab Vasc Dis Res Subsets: MEDLINE
- Publication Information: Publication: 2009- : London : Sage Publications
Original Publication: Edgbaston, Birmingham, UK : Sherborne Gibbs, c2005- - Subject Terms: Sodium-Glucose Transporter 2 Inhibitors*; Blood Glucose/*drug effects ; Canagliflozin/*therapeutic use ; Diabetes Mellitus, Type 2/*drug therapy ; Diabetic Nephropathies/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Kidney/*drug effects ; Renal Insufficiency, Chronic/*drug therapy; Acetylglucosaminidase/urine ; Aged ; Albuminuria/drug therapy ; Albuminuria/etiology ; Albuminuria/physiopathology ; Biomarkers/blood ; Biomarkers/urine ; Blood Glucose/metabolism ; Canagliflozin/adverse effects ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetic Nephropathies/blood ; Diabetic Nephropathies/etiology ; Diabetic Nephropathies/physiopathology ; Disease Progression ; Fatty Acid-Binding Proteins/urine ; Female ; Glomerular Filtration Rate/drug effects ; Humans ; Hypoglycemic Agents/adverse effects ; Japan ; Kidney/metabolism ; Kidney/physiopathology ; Male ; Middle Aged ; Prospective Studies ; Renal Insufficiency, Chronic/blood ; Renal Insufficiency, Chronic/etiology ; Renal Insufficiency, Chronic/physiopathology ; Sodium-Glucose Transporter 2/metabolism ; Time Factors ; Treatment Outcome ; beta 2-Microglobulin/urine
- Abstract: Background: To evaluate the renoprotective effects of canagliflozin, we assessed the albuminuria-lowering effect in Japanese type 2 diabetes patients with chronic kidney disease (CKD).
Methods: In this prospective, open-label, parallel-group study, type 2 diabetes patients with CKD were randomized to receive either oral canagliflozin (100 mg/day) or usual care (control group) for 52 weeks. Endpoints included changes in urinary albumin-to-creatinine ratio (UACR), other urinary biomarkers, laboratory parameters, and adverse events.
Results: Both groups included 20 patients in the analysis. Mean changes in UACR was -83 (-266 to -31) mg/gCr and 27 (-11 to 131) mg/gCr, in the canagliflozin and control groups, respectively ( p = 0.004). Urinary liver-type free acid binding protein, N-acetyl-β-d-glucosaminidase, and β2 -microglobulin levels were also significantly decreased in the canagliflozin group, but not in the control group. Mean change in estimated glomerular filtration rate at the end of the study was 0.7 and -3.4 mL/min/1.73 m 2 in the canagliflozin and control group, respectively ( p = 0.024). Canagliflozin treatment led to improvement of glycaemic control and reduction in body weight, blood pressure, and liver transaminase. There were no adverse events associated with canagliflozin.
Conclusion: Canagliflozin was associated with slower progression of kidney disease and reduction in albuminuria and tubulointerstitial markers in diabetes patients with CKD. - Contributed Indexing: Keywords: Albuminuria; canagliflozin; chronic kidney disease; type 2 diabetes
- Accession Number: 0 (Biomarkers)
0 (Blood Glucose)
0 (FABP1 protein, human)
0 (Fatty Acid-Binding Proteins)
0 (Hypoglycemic Agents)
0 (SLC5A2 protein, human)
0 (Sodium-Glucose Transporter 2)
0 (Sodium-Glucose Transporter 2 Inhibitors)
0 (beta 2-Microglobulin)
0SAC974Z85 (Canagliflozin)
EC 3.2.1.52 (Acetylglucosaminidase) - Publication Date: Date Created: 20180621 Date Completed: 20181009 Latest Revision: 20181202
- Publication Date: 20231215
- Accession Number: 10.1177/1479164118782872
- Accession Number: 29923427
- Source:
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.